Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

114.70USD
20 Oct 2017
Change (% chg)

$-0.93 (-0.80%)
Prev Close
$115.63
Open
$115.61
Day's High
$115.61
Day's Low
$111.38
Volume
625,524
Avg. Vol
411,514
52-wk High
$126.00
52-wk Low
$31.39

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.94
Market Cap(Mil.): $10,521.82
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

CORRECTED-UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment

Oct 18 Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.

Oct 18 2017

CORRECTED-Alnylam, Vir partner on RNAi-based drugs for infectious diseases

Oct 18 Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B.

Oct 18 2017

Alnyalm, Vir partner on RNAi-based hep B treatment

Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.

Oct 18 2017

BRIEF-Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases

* Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases

Oct 18 2017

BRIEF-Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5)

* Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5) in patients with atypical hemolytic-uremic syndrome (aHUS)

Sep 26 2017

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.

Sep 20 2017

UPDATE 4-Alnylam's RNAi drug succeeds in key study, shares soar

* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse

Sep 20 2017

BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study

* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy

Sep 20 2017

Alnylam's genetic disease drug meets main goal in key study

Sept 20 Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.

Sep 20 2017

Alnylam stock plummets after patient death in hemophilia study

Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died, sending its shares sharply down.

Sep 07 2017

Earnings vs. Estimates